🏴‍☠️🌸𝒢𝑜𝓁𝒹𝓎 𝑀𝒶𝓇𝒾𝑒 𝒜𝓃𝒹𝓇𝑒𝓌𝓈🌸🏴‍☠️

The peptide industry is about to undergo a massive transformation. CNN just featured my perspective on the proposed federal policy that could change how Americans access peptides. HHS is moving toward allowing six peptides, including BPC-157, TB-500, KPV, MOTS-c, Semax, and Epitalon, to be compounded through licensed pharmacies under specific conditions. This is potentially a major step forward for physician-guided access. But there's a side of this conversation that most people aren't paying attention to. COST. Greater regulatory oversight, pharmaceutical sourcing requirements, and extensive quality testing all come with a price. And guess who ultimately pays for that? The consumer. As I told CNN: "People who have been paying research-market prices should be prepared for a very different bill at the pharmacy counter." I've spent years educating people about peptides, their potential, and the importance of quality, transparency, and responsible use. I AM absolutely in favor of raising industry standards. But we cannot create a system where greater oversight comes at the expense of affordability and accessibility. And here's what people need to understand. This proposed policy addresses prescription compounding.  It does NOT resolve what happens to the direct-to-consumer research peptide market. That's a massive distinction. We're entering a pivotal period for the peptide industry, and the decisions being made right now could shape its future for years to come. Read the full article and my perspective here: lnkd.in/eSY28iFN